Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This topical combination consists of 5% 5-fluorouracil (5-FU) cream mixed with petroleum jelly (Vaseline). It was specifically utilized as the control preparation in a Phase 2 clinical trial (NCT02019355) conducted by Massachusetts General Hospital. The active component, 5-fluorouracil, is a pyrimidine antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase, thereby inducing cell death in rapidly proliferating dysplastic keratinocytes. Petroleum jelly serves as an emollient and occlusive vehicle in this formulation. The trial investigated whether a combination of calcipotriol and 5-FU was superior to this 5-FU plus petroleum jelly control for the treatment of actinic keratosis and the prevention of progression to cutaneous squamous cell carcinoma, particularly in organ transplant recipients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-fluorouracil + petroleum jelly (Massachusetts General Hospital).